HeRO Graft Clinical Data
Understand the clinical data and outcomes as Dr. Jeffrey H. Lawson and Shawn M. Gage, PA–C discuss the published data on HeRO Graft.
Fewer infections
- 69% reduced infection rate compared with catheters1
Superior Dialysis Adequacy
- 1.7Kt/V, a 16% to 32% improvement compared with catheters1
High Patency Rates
- Up to 87% cumulative patency at 2 years1,2
Cost Savings
- A 23% average savings per year compared with catheters3
Clinical Outcomes
| HERO GRAFT GAGE, ET AL. EJVES2 | HERO GRAFT KATZMAN, ET AL. JVS1 | CATHETER LITERATURE1 | AV GRAFT LITERATURE1 | |
|---|---|---|---|---|
| Bacteremia Rates (Infections/1,000 days) | 0.14 | 0.70 | 2.3 | 0.11 |
| Adequacy of Dialysis (mean Kt/V) § | N/A | 1.7 | 1.29-1.46 | 1.37-1.62 |
| Cumulative Patency (at 1 year) | 91% | 72%ǂ | 37% | 65% |
| Intervention Rate (per year) | 1.5 | 2.5 | 5.8 | 1.6-2.4 |
§ Note: Every 0.1 decrease in Kt/V increases the mortality rate by 7%4 and is significantly (P<0.05) associated with 11% more hospitalizations, 12% more hospital days, and a $940 increase in Medicare inpatient expenditures.5
ǂ 8.6 months
References
- Katzman, MD, et al., J Vasc Surg 2009.
- Gage et al., EJVES 2012.
- Dageforde et al., JSR 2012.
- Dhingra et al., Kidney Int 2001.
- 2006 NKF KDOQI, Guideline 4.
